Subscribe To
ALGS / Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
ALGS News
By GlobeNewsWire
June 7, 2023
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company fo more_horizontal
By GlobeNewsWire
May 24, 2023
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company foc more_horizontal
By Zacks Investment Research
May 4, 2023
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compar more_horizontal
By GlobeNewsWire
April 11, 2023
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company f more_horizontal
By Zacks Investment Research
March 9, 2023
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do more_horizontal